科學技術-科研成果

專注给予質高價優

的生物藥

科學論文

Pei-Hua Lin, Chi-Ling Tseng, Yun-Chih Cheng, Chieh-Hsin Ho, Shih Chieh Chen, Yanling Wang, Eugene Liu, Hassan Issafras & Weidong Jiang (2021) Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy, Expert Opinion on Biological Therapy, 21:11, 1491-1507, DOI: 10.1080/14712598.2021.1988072.
Expert Opinion on Biological Therapy
Cai, L., Li, L., Cheng, H. et al. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther (2021). http://doi.org/10.1007/s12325-021-01899-0
Advances in Therapy
Manuscript: Xu, Y.; Xie, L.; Zhang, E.; Gao, W.; Wang, L.; Cao, Y.; Xie, M. H.; Jiang, W.; Liu, S., Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®. mAbs 2019, 1-15.
Preclinical data published on mAbs
Poster: Mengmeng Zhao, Ying Xiang, et al. the Cost-effectiveness and Budget Impact Analysis of Rituximab (Hanlikang) for Patients with Diffuse Large B-cell Lymphoma in China.
ISPOR 2019
Oral: Xu, B.; Zhang, Q.; Sun, T.; Li, W.; Teng, Y.; Hu, X.; Bondarenko, I.; Adamchuk, H.; Zhang, L.; Trukhin, D.; Li, B.; Shan, B.; Cheng, J.; Peng, T.; Jiang, W.; Liu, S.; Zhang, X.; Wang, Q.; Liu, E.; Luk, A., 309PDEfficacy and safety of first China-manufactured trastuzumab biosimilar HLX02 for metastatic breast cancer: A phase III trial. Annals of Oncology 2019, 30 (suppl_5), mdy242.004.
CSCO 2019
Poster: China-manufactured adalimumab biosimilar, HLX03, demonstrated pharmacokinetic equivalence and comparable safety to reference adalimumab.
EULAR 2019

知識產權

專利申請數量	PCT申請數量	國內外授權專利數量	註冊司法權區	申請日期	到期日	發明專利數量
809	90	134	中國大陸	2011-03-18	2031-03-18	97

云顶集团(中国)